-+ 0.00%
-+ 0.00%
-+ 0.00%

Scotiabank Maintains Sector Outperform on Myriad Genetics, Lowers Price Target to $20

Benzinga·04/01/2025 14:34:54
Listen to the news
Scotiabank analyst Sung Ji Nam maintains Myriad Genetics (NASDAQ:MYGN) with a Sector Outperform and lowers the price target from $24 to $20.